![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, March 10, 2021 3:55:58 PM
By: Leah PezzettiPosted at 5:20 PM, Mar 09, 2021
SAN DIEGO, Calif. (KGTV) - San Diego-based company Sorrento Therapeutics and Mount Sinai are collaborating on the further development of monoclonal antibodies for therapeutic applications.
The antibodies should be able to fight any variant of coronavirus.
Sorrento currently has treatments undergoing clinical trials that can be given in two different ways. The first way is through an IV, a process that takes 2-3 minutes. The second way is through drops in the nose, which ideally will be a simple tactic to use if a person tests positive.
“You go to CVS, pick it up, put a few drops in your nose and prevent the virus from replicating, gets injected into the lung and preventing you from spreading the virus,” said Henry Ji, Chairman and CEO of Sorrento Therapeutics.
He said the antibody they have created is more potent, meaning they can make more doses. This will create more access to protection against the virus. It is also expected to only cost a few hundred dollars, which is a cheaper alternative than spending tens of thousands for an infusion in a hospital.
“So for the average person, it gives them hope, getting a diagnosis of COVID, if they haven’t been vaccinated or the vaccine did take, they now have additional options to prevent anything serious from happened,” said Mark Brunswick, Senior Vice President for Regulatory Affairs and Quality.
Ji said the part of their antibody that they’re most excited about is the fact that they believe it should fight against all known strains of the virus, including the UK strain, the South African strain, and the Japan/Brazil strain.
Their “vaxi-body,” which is a vaccine antibody, should not only treat people who have tested positive but also protect against any future exposures, similar to what current vaccines are doing. That prevention paired with the protection against all known strain is important moving forward as other variants have the possibility of becoming more prevalent, and also people need follow-up doses in the future.
“It’s definitely not a one-and-done vaccine and if this virus keeps on mutating, escaping all of the immunity you established, it’s going to be multi-years. That’s why the whole world, scientists are working on this to solve the problem,” said Ji.
Sorrento is currently putting these antibodies through trials with healthy volunteers and hopes to complete the trials by the end of 2021.
"The refusal of the real is the number one dogma of our time" Rene Girard
Recent SRNE News
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 09:31:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:15:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 01:51:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2023 09:25:07 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/07/2023 08:15:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2023 10:01:54 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/13/2023 10:26:26 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM